Erasca (ERAS) Net Income towards Common Stockholders (2020 - 2026)
Erasca (ERAS) posted Net Income towards Common Stockholders of -$860.7 million for Q1 2026, down 2423.74% on a QoQ basis from -$34.1 million in Q4 2025, and down 2218.06% year-over-year from $40.6 million in Q1 2025.
Erasca (ERAS) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Erasca's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$860.7 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 2218.06% year-over-year to -$860.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.0 billion (down 267.67% YoY) and the FY2025 annual result came in at -$383.1 million, down 98.94% from the prior year.
- Net Income towards Common Stockholders was -$860.7 million for Q1 2026 at Erasca, down from -$34.1 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$34.1 million in Q4 2025 and bottomed at -$860.7 million in Q1 2026.
- A 5-year average of -$118.7 million and a median of -$55.7 million in 2025 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders soared 74.06% — and 2026, when it sank 2218.06%.
- Erasca's Net Income towards Common Stockholders stood at -$139.1 million in 2022, then surged by 74.06% to -$36.1 million in 2023, then decreased by 3.71% to -$37.4 million in 2024, then grew by 8.84% to -$34.1 million in 2025, then sank by 2423.74% to -$860.7 million in 2026.
- Business Quant data shows ERAS's Net Income towards Common Stockholders at -$860.7 million in Q1 2026, -$34.1 million in Q4 2025, and -$51.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Erasca | 5.84 Bn | 5.84 Bn | - | -860.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -860.70 Mn |
| Dec 31, 2025 | -34.10 Mn |
| Sep 30, 2025 | -51.08 Mn |
| Jun 30, 2025 | -55.74 Mn |
| Mar 31, 2025 | -37.13 Mn |
| Dec 31, 2024 | -37.41 Mn |
| Sep 30, 2024 | -53.90 Mn |
| Jun 30, 2024 | -143.98 Mn |
| Mar 31, 2024 | -46.38 Mn |
| Dec 31, 2023 | -36.07 Mn |
| Sep 30, 2023 | -60.57 Mn |
| Jun 30, 2023 | -120.78 Mn |
| Mar 31, 2023 | -45.78 Mn |
| Dec 31, 2022 | -139.07 Mn |
| Sep 30, 2022 | -124.98 Mn |
| Jun 30, 2022 | -66.60 Mn |
| Mar 31, 2022 | -103.70 Mn |
| Dec 31, 2021 | -31.35 Mn |
| Sep 30, 2021 | -288.26 Mn |
| Jun 30, 2021 | -110.92 Mn |